EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application lacosamide tablets USP, 50mg, 100mg, 150mg, and 200mg. Aurobindo Pharma’s lacosamide tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), VIMPAT Tablets manufactured by UCB, Inc.
Lacosamide tablets, are indicated as monotherapy or adjunctive therapy in patients with partial onset seizures
Lacosamide tablets, has an estimated market size of US $971 Million for the twelve months ending November 2022, as per IQVIA.
